Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids
by Kinjel Shah
FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.
J&J (JNJ) Gets First Full Approval for COVID Jab in Canada
by Zacks Equity Research
Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.
Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year
by Zacks Equity Research
Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.
FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults
by Zacks Equity Research
The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.
Stock Market News for Nov 22, 2021
by Zacks Equity Research
Wall Street closed mixed on Friday to end a choppy week.
FDA Gives Authorization to Two COVID-19 Boosters
by Zacks Equity Research
FDA Gives Authorization to Two COVID-19 Boosters
FDA Authorizes Covid Boosters; New Fed Chair Soon?
by Mark Vickery
Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.
by Zacks Equity Research
The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.
Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill
by Kinjel Shah
J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
Goldman Fans Can Reap Returns From S&P 500 ETFs in 2022
by Sanghamitra Saha
Goldman Sachs (GS) this week said that it expects the S&P 500 to rise 9% to 5,100 by the end of 2022, as quoted on a Yahoo Finance article.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up
by Zacks Equity Research
J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.
Pre-Markets Edge Up on JNJ Split News
by Zacks Equity Research
Pre-Markets Edge Up on JNJ Split News
J&J Plans to Split in Two; Dow Up Triple Digits
by Mark Vickery
In order to focus on market growth in its Pharma division, Johnson & Johnson now plans to split its Consumer Health business into a separate entity.
Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill's Strong Efficacy
by Kinjel Shah
AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.